Chiasma Presents Long-Term Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly at ENDO 2021
–93% of all patients who enrolled as a responder to MYCAPSSA® maintained their biochemical response…
Philippine Tourism Has Three Arrival Counters and a 300,000 Gap
CIMC Group Announces Results for the First Three Quarters of 2026
U.S. Polo Assn. Executes Early on Europe’s Digital Product Passport Mandate
COSCO SHIPPING Ports Announces 2026 Third Quarter Results
Beyond the Hype: Singapore’s Aivo Asia Scales Unified SaaS Platform to Drive Real Business Growth Through Conversational AI